Guggenheim upgraded Oric Pharmaceuticals to Buy from Neutral with a $15 price target. The company is now nearing first clinical Phase I proof of concept data in the second half of 2023 on three pipeline agents, ORIC-144, ORIC-533 and ORIC-944, the analyst tells investors in a research note. The firm says Oric shares currently trade near cash, reflecting only minimal value for the pipeline priced in currently. As such, it sees an "asymmetric risk/reward" heading into the second half of the year with limited potential downside.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ORIC:
- Oric Pharmaceuticals reports Q4 EPS (52c), consensus (55c)
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates
- Oric Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
- ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals to Participate in the Oppenheimer 33rd Annual Healthcare Conference